Preview

Медицинский Совет

Расширенный поиск

Цитиколин при ишемическом инсульте: от острого периода к реабилитации

https://doi.org/10.21518/2079-701X-2015-18-6-10

Полный текст:

Аннотация

Применение эффективной патогенетической терапии ишемического инсульта - реперфузионных вмешательств - существенно ограничено необходимостью тщательного отбора пациентов и организации службы специализированной помощи. В связи с этим особое значение приобретают фармакологические методы лечения, направленные на поддержание жизнеспособности нейронов в зоне ишемии. К наиболее изученным и перспективным нейропротекторам относится цитиколин. Препарат улучшает исход у отдельных групп пациентов с острым ишемическим инсультом, а также оказывает благоприятный эффект в отношении когнитивных функций в восстановительном периоде. Кроме того, существуют свидетельства эффективности препарата в отношении восстановления функции верхней конечности у пациентов с гемиплегией. Цитиколин можно рекомендовать как в остром периоде ишемического инсульта, так и на этапе реабилитации.

Об авторах

Д. В. Сергеев
Научный центр неврологии
Россия


М. А. Домашенко
Научный центр неврологии
Россия


М. А. Пирадов
Научный центр неврологии
Россия


Список литературы

1. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al; American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare profession- als from the American Heart Association/American Stroke Association. Stroke. 2013. 44: 870-947.

2. Powers WJ, Derdeyn CP, Biller J, Coffey CS, Hoh BL, Jauch EC, et al; American Heart Association Stroke Council. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare profession- als from the American Heart Association/American Stroke Association. Stroke. 2015. 46: 3020-3035.

3. Vahedi K, Hofmeijer J, Juettler E, Vicaut E, George B, Algra A, Amelink GJ, Schmiedeck P, Schwab S, Rothwell PM, Bousser MG, van der Worp HB, Hacke W; DECIMAL, DESTINY, and HAMLET investiga- tors. Early decompressive surgery in malignant infarction of the middle cerebral artery: a pooled analysis of three randomised controlled trials. Lancet Neurol. 2007. 6: 215-222.

4. Emberson J, Lees KR, Lyden P et al. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014 Nov 29. 384(9958): 1929-35.

5. Kahn J, Viereck J, Kase C et al. The use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke. J Emerg Med, 2005. 29: 273-277.

6. Davalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012 Jul 28. 380(9839): 349-57.

7. Nasr DM, Brinjikji W, Cloft HJ, Rabinstein AA. Utilization of intravenous thrombolysis is increasing in the United States. Int J Stroke. 2013 Dec. 8(8): 681-8.

8. Grupke S, Hall J, Dobbs M, Bix GJ, Fraser JF. Understanding history, and not repeating it. Neuroprotection for acute ischemic stroke: from review to preview. Clin Neurol Neurosurg. 2015 Feb. 129: 1-9.

9. Kennedy E. Sailing to Byzantium. Ann. Rev. Biochem. 1992 61: 1-28.

10. Watanabe S, Kono S, Nakashima Y et al. Effects of various cerebral metabolic activators on glucose metabolism of brain. Folia Psychiatr. Neurol. Jpn. 1975. 29: 67-76.

11. Martinet M, Fonlupt P, Pacheco H. Effects of cytidine-5' diphosphocholine on norepineph-rine, dopamine and serotonin synthesis in various regions of the rat brain. Arch. Int Pharmacodyn. Ther. 1973. 239: 52-61.

12. Secades J, Frontera G. CDP-choline: pharmacological and clinical review. Methods Find Exp. Clin. Pharmacol. 1995. 17 (Suppl. B): 1-54.

13. Zafonte R, Bagiella E, Ansel B et al: Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT). JAMA. 2012. 308: 1993-2000.

14. Secades JJ. Citicoline: pharmacological and clinical review, 2010 update. Rev Neurol 2011. 52(Suppl 2): S1-S62.

15. Gutierrez-Fernandez M, Rodriguez-Frutos B, Fuentes B, et al. CDP-choline treatment induces brain plasticitymarkers expression in experimental animal stroke. NeurochemInt. 2012. 60: 310-317.

16. Grieb P. Citicoline: A Food That May Improve Memory. Med. Sci. Rev. 2015. 2: 67-72.

17. Fioravanti M., Yanagi M. Cytidinedi-phosphocholine (CDP-choline) for cognitive and behavioral disturbances associated with chronic cerebral disorders in the elderly. Cochrane Database Syst. Rev. 2005. 2: CD000269.

18. Alvarez-Sabin J, Ortega G, Jacas C et al: Long-term treatment with citicoline may improve poststroke vascular cognitive impairment. Cerebrovasc. Dis. 2013. 35: 146-54.

19. Tham W, Auchus AP, Thong M, Chang HM, Wong MC, Chen CP: Progression of cognitive impairment after stroke: one year results from a longitudinal study of Singaporean stroke patients. J Neurol Sci. 2002. 203-204: 49-52.

20. Madureira S, Guerreiro M, Ferro JM: Dementia and cognitive impairment three months after stroke. Eur J Neurol. 2001. 8: 621-627.

21. Rasquin SMC, Verhey FRJ, van Oostenbrugge RJ, Lousberg R, Lodder J: Demographic and CT scan features related to cognitive impairment in the first year after stroke. J Neurol Neurosurg Psychiatry. 2004. 75: 1562-1567.

22. Jaillard A, Grand S, Francois Le Bas J, Hommel M: Predicting cognitive disfunctioning шт non-demented patients early after stroke. Cerebrovasc Dis. 2010. 29: 415-423.

23. Reitz C, Bos MJ, Hofman A, Koudstaal PJ, Breteler MMB: Prestroke cognitive performance, incident stroke, and risk of dementia. The Rotterdam study. Stroke. 2008. 39: 36-41.

24. Hurtado O, Cardenas A, Pradillo JM, Morales JR, Ortego F, Sobrino T, Castillo J, Moro MA, Lizasoain I: A chronic treatment with CDPcholine improves functional recovery and increases neuronal plasticity after experimental stroke. Neurobiol Dis. 2007. 26: 105-111.

25. Alvarez-Sabin J, Roman GC. Citicoline in vascular cognitive impairment and vascular dementia after stroke. Stroke. 2011 Jan. 42(1 Suppl): S40-3.

26. Cotroneo AM, Castagna A, Putignano S, et al. Effectiveness and safety of citicoline in mild vascular cognitive impairment: the IDEALE study. Clin IntervAging. 2013. 8: 131-7. doi: 10.2147/CIA.S38420. Epub 2013 Feb 5.

27. Hazama T, Hasegawa T, Ueda S, Sakuma A. Evaluation of the effect of CDP-choline on poststroke hemiplegia employing a double-blind controlled trial. Assessed by a new rating scale for recovery in hemiplegia. Int J Neurosci. 1980. 11(3): 211-25.

28. Ueda S, Hasegawa T, Ando K et al. Evaluation of the pharmacological effect of CDP-choline injection in post-stroke hemiplegia. Double-blind comparative study using the Hemiplegia Function Test (12-grade evaluation method). Strides of Medicine. 1994. 170: 297-314.

29. Secades JJ. Probably role of citicoline in stroke rehabilitation: review of the literature. Rev Neurol. 2012 Feb 1. 54(3): 173-9.


Просмотров: 92


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 2079-701X (Print)
ISSN 2658-5790 (Online)